Cocrystal's lead covid-19 antiviral cdi-45205 shown to be active against sars-cov-2 and two prominent sars-cov-2 variants

Bothell, wash., june 14, 2021 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis c viruses and noroviruses, announces that its lead preclinical sars-cov-2 3cl protease inhibitor cdi-45205 is active against sars-cov-2 and two prominent sars-cov-2 variants.
COCP Ratings Summary
COCP Quant Ranking